Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Daniel George, MD, discusses results from a study analyzing real-world utilization of advanced therapies for patients with metastatic CSPC over time by metastatic site and age.
Daniel George, MD, discusses results from a study analyzing real-world utilization of advanced therapies for patients with metastatic CSPC over time by metastatic site and age.
Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate formulations on testosterone suppression for patients with prostate cancer.
Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate formulations on testosterone suppression for patients with prostate cancer.
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Barry Tong, CGC, MS, MPH, discusses a study evaluating the effectiveness of a prostate Genetic Testing Station at UCSF and compared these outcomes to those of a previously implemented take-home method.
Barry Tong, CGC, MS, MPH, discusses a study evaluating the effectiveness of a prostate Genetic Testing Station at UCSF and compared these outcomes to those of a previously implemented take-home method.
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and prostatectomy procedures between 2010 and 2019 and comparing these to minimally invasive approaches.
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and prostatectomy procedures between 2010 and 2019 and comparing these to minimally invasive approaches.
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...